Sandoz, a Novartis division, has launched Desflurane, Liquid for Inhalation, the first generic of Suprane® in the US, as an inhalation agent for induction and maintenance of anesthesia for inpatient and outpatient surgery in adults, and for maintenance of anesthesia for inpatient and outpatient surgery in pediatric patients.
Sandoz is launching Desflurane, USP, through collaboration with Jiangsu Hengrui Medicine Co., the owner of the product’s Abbreviated New Drug Application (ANDA).
Desflurane is the only available generic of Suprane® 240 mL liquid by Baxter Healthcare Corporation. According to IQVIA, the current market size for Desflurane is USD 128 million for the period ending November 2018 (MAT: Moving Annual Target).
As we continue to reimagine medicine, Sandoz US has focused its strategy on specialization in biosimilars, Value-Added Medicines (VAMs), complex generics and prescription digital therapeutics, to contribute to helping patients gain access to cost-effective and advanced health treatments. This launch – the Company’s third launch in the US this month – is another example of how we are delivering on our strategy to drive portfolio transformation with complex generics such as Desflurane, while simultaneously delivering on our promise to patients.
We are confident the availability of Sandoz Desflurane will have a positive impact on patients who are administered this medicine in the operating room.